Eli Lilly is aggressively expanding its presence in the weight-loss drug market by announcing a $2.3 billion acquisition of Ajax Therapeutics and enhancing its AI-driven drug discovery efforts. Despite facing competition from Novo Nordisk, the company has seen a surge in market interest, highlighted by a recent price target increase from Wolfe Research. As investors prepare for Eli Lilly's earnings report, the strong consensus 'Strong Buy' rating emphasizes confidence in its growth potential, despite recent stock volatility.
“I’m a Eli Lilly guy, okay? I’m going to stick with it.”
“Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.”
“Lilly, on the other hand, has a decades-long history of navigating regulatory landscapes.”
“Lilly, with a $200 billion market cap, trades at a forward P/E of 21x.”
“Its dividend yield of 2.3% adds downside protection.”
“Today, Eli Lilly and Novo Nordisk dominate the GLP-1 drug market, selling Zebound and Wegovy, respectively.”
“Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery”
“We'll also get earnings from Eli Lilly tomorrow, which comes as the stock has more than tripled in the last three years.”
“Novo Nordisk has awarded its new clinical stage company CanEli Lilly to acquire Centessa.”
“Fair Value:US$1.48k35.4% undervalued”
“Eli Lilly to Acquire Blood Cancer Drug Developer for Up to USD2.3B”
“Eli Lilly to Acquire Blood Cancer Drug Developer for Up to USD2.3B”
